Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation-Wide Study by the Italian Melanoma Intergroup (IMI).

Melanoma, a serious type of skin cancer, is often driven by mutations in a gene called BRAF. Doctors typically look for the most common versions of this mutation to decide if a patient can receive specific targeted drugs. However, there are other, much rarer BRAF mutations that are less understood. Recently, researchers from the Italian Melanoma Intergroup looked back at patient records to see how these unusual mutations behave. Across 19 medical centers, they analyzed over 14,000 melanoma samples and found that 1.8 percent of the cases harbored rare BRAF mutations.

The research team compared how patients with these rare mutations fared on different cancer treatments. Targeted therapies use special drugs, often combining a BRAF inhibitor with a MEK inhibitor, to directly block the cancer-causing protein. The study revealed that patients with rare BRAF mutations survived and lived without their disease worsening for about the same amount of time as patients with the standard mutation. While the initial response rate to the targeted drugs was lower for the rare group at 48 percent compared to 66 percent for the standard group, this difference was not mathematically significant. For patients treated with immunotherapy, which boosts the immune system to fight cancer, the specific type of BRAF mutation did not change their survival outcomes.

To understand why these targeted drugs still work, the scientists used computer simulations to look at the physical shape of the mutated proteins. They discovered that rare mutations located near the usual genetic hotspot cause the protein to become unstable and stay permanently switched on, which drives cancer growth in a similar way to the common mutation. The researchers did note some limitations, pointing out that their study looked backward at past patient data rather than running a new clinical trial. Additionally, because the group of patients with rare mutations was small, it is possible the lowered response rate to targeted therapy might still be important, requiring larger studies to fully understand.